Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Prism Johnson Limited (PRSMJOHNSN.NS)
Mumbai, IN
Prism Johnson Limited functions as a multifaceted enterprise specializing in building materials, supplying cement, ready-mixed concrete, tiles, sanitaryware, and bath fittings across India and internationally. The company's operations are divided into four main segments: Cement, Tile and Bath (HRJ), Ready Mixed Concrete (RMC), and Insurance. In its Cement division, Prism Johnson manufactures Portland pozzolana cement, marketed under brands like Champion, Champion Plus, and Duratech, alongside Ordinary Portland Cement. This segment also includes the supply of aggregates and the management of quarries and crushers. Under the Tile and Bath division, the company offers a wide selection of ceramic and vitrified tiles, sanitaryware, bath fittings, faucets, accessories, and engineered marble and quartz products. These items are sold under prominent brand names such as Johnson, Johnson Marbonite, Johnson Porselano, Johnson Endura, and Johnson International. Additionally, the company engages in the general insurance business. Founded in 1992, the firm was formerly known as Prism Cement Limited, changing its name to Prism Johnson Limited in April 2018. Its corporate headquarters are situated in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.11% | -3.54% | +1.41% | +2.68% | -13.49% | -6.58% | -12.12% | +7.67% | -9.48% | +41.03% | +1,538.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Construction Materials: +2.8%+1.0% Q1'26: +0.4% (vs Q1'25)
-
EPS growth Construction Materials: +14.1%-8.8% Q1'26: -94.9% (vs Q1'25)
-
FCF margin FCF growth · Construction Materials: +32.9%+1.2% ★ Q1'26: -14.3% (vs Q1'25)
-
EBIT margin Construction Materials: +9.5%+2.2% Q1'26: +2.2% (vs Q1'25)
-
ROIC Construction Materials: +5.1%+4.3% Q1'26: +6.9% (vs Q1'25)
-
Share dilution Construction Materials: +0.0%+0.0% Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Construction Materials: 0.56×2.05× Q1'26: 2.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2010 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 2 EPS Ana. |
Mar 2028 3 Rev. Ana. 2 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
28.75B
est: 6.37B (+351.6%)
|
49.93B
est: 49.05B (+1.8%)
|
55.84B
est: 56.40B (-1.0%)
|
55.44B
est: 57.35B (-3.3%)
|
49.82B
est: 55.90B (-10.9%)
|
54.82B
est: 53.88B (+1.7%)
|
61.51B
est: 60.69B (+1.3%)
|
59.20B
est: 60.70B (-2.5%)
|
55.87B
est: 52.54B (+6.3%)
|
63.06B
est: 60.85B (+3.6%)
|
73.61B
est: 69.91B (+5.3%)
|
73.94B
est: 75.23B (-1.7%)
|
73.10B
est: 74.31B (-1.6%)
|
78.29B
78.13B – 78.44B
+5.4% YoY
|
80.48B
77.55B – 82.72B
+2.8% YoY
|
84.41B
78.37B – 89.04B
+4.9% YoY
|
89.06B
85.82B – 91.54B
+5.5% YoY
|
| EBITDA |
5.48B
est: 541.42M (+912.1%)
|
3.46B
est: 32.53B (-89.4%)
|
4.52B
est: -540.63M (+936.9%)
|
4.94B
est: -1.05B (+572.2%)
|
4.55B
est: -103.89M (+4,475.5%)
|
5.17B
est: 209.41M (+2,366.6%)
|
6.22B
est: 760.51M (+717.9%)
|
5.57B
est: 1.90B (+192.6%)
|
6.62B
est: 911.26M (+626.3%)
|
5.72B
est: 1.10B (+417.5%)
|
3.99B
est: 1.07B (+272.0%)
|
7.74B
est: 6.37B (+21.5%)
|
4.18B
est: 7.33B (-42.9%)
|
7.72B
7.71B – 7.74B
+5.4% YoY
|
7.94B
7.65B – 8.16B
+2.8% YoY
|
8.33B
7.73B – 8.79B
+4.9% YoY
|
8.79B
8.47B – 9.03B
+5.5% YoY
|
| EBIT |
4.40B
est: 189.33M (+2,225.2%)
|
1.30B
est: 33.20B (-96.1%)
|
2.66B
est: -11.77M (+22,684.8%)
|
2.87B
est: 2.57B (+11.7%)
|
2.50B
est: 1.53B (+63.3%)
|
3.07B
est: 1.54B (+99.4%)
|
4.22B
est: 3.07B (+37.5%)
|
3.13B
est: 3.84B (-18.6%)
|
3.33B
est: 2.26B (+47.5%)
|
2.62B
est: 2.74B (-4.4%)
|
91.20M
est: 2.66B (-96.6%)
|
3.57B
est: 2.23B (+60.2%)
|
-650.60M
est: 1.55B (-141.8%)
|
1.64B
1.63B – 1.64B
+5.4% YoY
|
1.68B
1.62B – 1.73B
+2.8% YoY
|
1.77B
1.64B – 1.86B
+4.9% YoY
|
1.86B
1.80B – 1.92B
+5.5% YoY
|
| Net Income |
2.60B
est: 1.54B (+68.9%)
|
-862.00M
est: 20.02B (-104.3%)
|
26.20M
est: -1.01B (+102.6%)
|
33.00M
est: 26.82M (+23.1%)
|
-18.00M
est: 27.67M (-165.0%)
|
425.00M
est: -16.95M (+2,607.6%)
|
1.16B
est: 500.41M (+132.6%)
|
-206.50M
est: 1.15B (-118.0%)
|
1.71B
est: 13.26M (+12,815.2%)
|
917.70M
est: 16.07M (+5,611.3%)
|
-1.03B
est: 15.61M (-6,711.5%)
|
1.81B
est: 639.56M (+183.2%)
|
799.30M
est: -1.37B (+158.3%)
|
-301.66M
-312.59M – -287.41M
+78.0% YoY
|
486.00M
226.80M – 745.20M
+261.1% YoY
|
1.21B
835.35M – 1.58B
+148.3% YoY
|
1.36B
1.29B – 1.41B
+12.5% YoY
|
| SGA |
5.36B
est: 1.35B (+296.0%)
|
9.09B
est: 10.42B (-12.8%)
|
10.73B
est: 16.68B (-35.6%)
|
10.40B
est: 16.60B (-37.3%)
|
8.15B
est: 23.45B (-65.2%)
|
8.59B
est: 22.15B (-61.2%)
|
10.58B
est: 29.74B (-64.4%)
|
10.99B
est: 25.82B (-57.4%)
|
10.67B
est: 23.79B (-55.2%)
|
12.88B
est: 28.83B (-55.3%)
|
16.65B
est: 28.02B (-40.6%)
|
17.09B
est: 15.91B (+7.4%)
|
15.34B
est: 15.97B (-3.9%)
|
16.82B
16.79B – 16.85B
+5.4% YoY
|
17.29B
16.66B – 17.77B
+2.8% YoY
|
18.14B
16.84B – 19.13B
+4.9% YoY
|
19.13B
18.44B – 19.67B
+5.5% YoY
|
| EPS |
5.29
est: 3.06 (+72.9%)
|
-1.76
est: -3.98 (+55.8%)
|
0.05
est: 0.53 (-90.5%)
|
0.06
est: -0.57 (+110.5%)
|
-0.04
est: -0.46 (+92.2%)
|
0.84
est: 1.57 (-46.4%)
|
2.31
est: 2.58 (-10.5%)
|
-0.41
est: 1.90 (-121.6%)
|
3.40
est: 2.62 (+29.9%)
|
1.82
est: 4.50 (-59.6%)
|
-2.05
est: -0.63 (-228.0%)
|
3.60
est: 1.28 (+181.3%)
|
1.59
est: -2.73 (+158.3%)
|
-0.60
-0.62 – -0.57
+78.0% YoY
|
0.97
0.45 – 1.48
+261.1% YoY
|
2.40
1.66 – 3.14
+148.3% YoY
|
2.70
2.57 – 2.80
+12.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arun Kumar Agarwal | Chief Financial Officer | 14M | male |
| Shailesh Dholakia | Company Secretary & Compliance Officer | 7M | male |
| Prabir K. Ray | Chief Human Resources Officer | — | male |
| Raakesh Jain | Chief Executive Officer of Cement & Whole-Time Director | — | male |
| Rajnish Sacheti | Chief Legal Officer | — | male |
| Sanjeeva | President of Special Projects & Chief Commercial Officer | — | male |
| Sarat Kumar Chandak | Chief Executive Officer of HRJ Division & Executive Director | — | male |
| Aditya Bob Mahendru | Chief Innovation Officer | — | male |
| Vijay Aggarwal | MD & Executive Non-Independent Director | — | male |
| Ashish Samal | Chief Investor Relations Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRSMJOHNSN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
